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Abstract The INdian DIabetes COnsortium (INDICO) is
an initiative to build a resource for genetic, epigenetic and
clinical studies of type 2 diabetes (T2D) in socioeconom-
ically transiting Indians. The consortium aims to follow
selected communities which are undergoing rapid urbani-
zation over a period of years to create a knowledge base for
the better understanding of the gene-environment interac-
tion in T2D. These resources can eventually be of value to
not just the diabetes research community but would be able
to contribute towards an improved understanding, diagno-
sis and prevention of numerous complex human disorders.
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Introduction
India currently has *50.8 million adults with type 2 dia-
betes (T2D) which is estimated to rise to 87.0 million by
2030 (IDF Diabetes Atlas 2009). Most of this increase is
expected to be in the urban areas (Sicree et al. 2006;
Mohan et al. 2008; Mohan and Pradeepa 2009; Rama-
chandran et al. 2010; Unwin et al. 2010). Moreover,
another trend noticed is the earlier onset of T2D; shifting
from C40 to 30 years of age (Mohan et al. 2007). The
pathophysiology of T2D is complex, involving an array of
molecular pathways that further interact with various
environmental factors. Efforts to identify the genetic
architecture of T2D using candidate gene analysis and
genome-wide association studies (GWAS) have led to a
dramatic expansion in T2D genes (*40) in the last few
years. But none of the approaches have resulted in a
complete understanding of T2D, and only 10% of the
heritability could be explained by the genetic risk loci
identified so far (McCarthy 2010). Genetic factors alone
cannot explain the sudden outbreak of epidemic of T2D in
India. This can be attributed to increasing mechanization
and reduced physical activity that accompany the new
urban lifestyle in Indian society (Mohan and Pradeepa
2009; Unwin et al. 2010). The combination of urbanization
and sedentary lifestyle with an increase in energy intake
due to easy availability of high-fat, energy-dense fast foods
at reduced costs have been instrumental in increasing
obesity and metabolic abnormalities in the population
(Ramachandran 2003; Astrup et al. 2008). Urban residents
have also been known to exhibit higher levels of stress
hormone causing high fat, sugar, and insulin in the blood,
insulin resistance and eventually T2D (Ozcan et al. 2004).
Environment factors like age, diet, maternal nutrition
which are key modifiers of lifestyle diseases such as dia-
betes, obesity, dyslipidemia, hypertension, and cardiovas-
cular diseases (Lillycrop and Burdge 2011) lead to
epigenetic modifications of the genome. Epigenetic chan-
ges regulating gene expression has emerged in the last few
years as a potentially important contributor to disease risks.
In the absence of strong genetic predictors, epigenetic
changes in the genome may be a better readout for the
environmental influence and individual predisposition for
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T2D in population with different mutational and demo-
graphic histories.
India, encompassing one-sixth of the world population
and the second largest pool of T2D patients, with unique
risk phenotypes, and rapid socio-economic transitions,
provides a unique resource for dissecting pathogenesis of
T2D (Indian Genome Variation Consortium 2008) at an
epigenetic level. Thus, we initiated a nation-wide collab-
orative effort by establishing the INdian DIabetes COn-
sortium (INDICO) for the systematic, comprehensive, and
large-scale studies towards the understanding of T2D in
India.
The primary goal of INDICO is to build resources and
generate information to understand role of genetic, epi-
genetic as well as environmental factors in pathogenesis
of T2D. The consortium deemed the resource fabrication
pertinent to divulge the risk factors accountable for the
high vulnerability of Indians to T2D by identifying pre-
diagnostic markers at genetic, epigenetic, metabolite and
proteomic levels for managing T2D and other related life
style disorders. The collaborative work of the consortium
has led to a repository of samples (DNA, plasma, and
serum) of more than 17,000 subjects from two major
ethnic groups in India (Indo-European and Dravidians)
that have been well-characterized for anthropometric and
clinical markers (Fig. 1). The subjects’ recruitment pro-
cedures and ascertainment criteria are detailed in supple-
mentary material. The anthropometric and clinical
characteristics of the recruited subjects are provided in
Supplementary Table 1.
Future goals and developments
INDICO brings together the expertise and experience of
clinicians, scientists, and young researchers involved in
diabetes research from all over the country (Supplementary
Figure 1), that will lead to capacity building for high-end
genetic, epigenetic, and proteomic studies in India in terms
of sample repository, infrastructure, and skilled manpower.
The resources developed by INDICO can bestow: (1)
GWAS to discover genes associated with T2D and related
metabolic traits, (2) Effect of lifestyle transitions by re-
sampling from the same areas at regular intervals, (3) Gene
expression profiling of different tissues to identify differ-
entially expressed genes in T2D, (4) Deep re-sequencing to
discover rare variants with high penetrance, (5) Proteomic
and metabolite studies to develop pre-diagnostic markers
for T2D and related traits, (6) Metagenomics to understand
the difference in gut micro-biota in T2D and normal indi-
viduals, and (7) Exchange of knowledge and experiences
across the globe to counter disease burden.
Moreover, the consortium is also actively engaged in
identification of novel genes and pathways for T2D through
different strategies including in silico candidate gene pri-
oritization, in silico function prediction and in vitro func-
tional analyses (Sharma et al. 2010). The consortium
monitors the effects of urbanization on a population-in-
transition by re-sampling at regular intervals from the same
geographical locations. The time range of sample collec-
tion (2003–2011) coincides with the rapid increase in the
Gross Domestic Product (GDP) growth of the Indian
Fig. 1 Bio-repository of INDICO, its recruitment and ascertainment
process. DBP Diastolic blood pressure, DR Dravidian, FPG Fasting
plasma glucose, HbA1c Glycosylated hemoglobin, HC Hip circum-
ference, HDL-C High density lipoprotein cholesterol, hsCRP high
sensitivity C-reactive protein, IE Indo-European, LDL-C Low density
lipoprotein cholesterol, PD Pre-diabetic subjects, SBP Systolic blood
pressure, T2D Type 2 diabetic patients, TC Total cholesterol, TG
Triglycerides, WC Waist circumference, 2 hr PG 2 hr post-load
plasma glucose
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economy (World Development Indicator 2011). We have
already observed an apparent clinical shift in the major
biochemical parameters (lipid profile & Hb1Ac) in con-
gruence with the rise in GDP (Fig. 2) indicating an epi-
demiological transition in progress. This gives us an
unprecedented opportunity to probe the correlation, if any,
between genetic and epigenetic changes in the genome and
rapid changes in lifestyle.
The INDICO bio-repository opens up new avenues to
initiate large-scale studies that can unravel new risk factors
and pre-diagnostic markers at the genetic, epigenetic,
metabolite, and proteomic levels for T2D, its associated
and related traits. DNA repository will serve as a valuable
resource to understand the synergistic role of genetic and
epigenetic factors in the pathogenesis of T2D through
large-scale studies. Our previous candidate gene studies
which identified a couple of novel putative T2D genes,
(Tabassum et al. 2008, 2010) suggest that exploration of
genetic factors in Indian population can lead to better
understanding of T2D. This huge DNA repository also
provides opportunity to discover rare variants for T2D that
will be a testimony for the ‘‘mosaic model’’ (Sharma et al.
2005) which propose that T2D results from interactions
among large number of rare alleles, smaller number of
common alleles and the environment. Recently we have
completed the genotyping of the first type 2 diabetes
GWAS in Indian population using the 610 Quad chips. We
expect this GWAS to not only reveal novel loci for T2D
but also serve as a dataset for GWA analysis for large
number of anthropometric and quantitative metabolic traits
such as BMI, blood pressure, plasma glucose, lipids, etc.
Apart from this, the whole genome genotyping data of
the 1,250 controls which are well characterized can also
be used as control dataset for number of other complex
disorders such as type 1 diabetes, chronic pancreatitis,
hypertension, polycystic kidney disorder etc. Proteome
analysis at different pre-disease and disease states can lead
to the identification of protein and metabolic biomarkers
that may be predictive of the disease manifestation. Dif-
ferential gene expression and methylation profiles would
be a key to mechanistically dissecting the development of
the disease and identifying novel drug targets. To aid this,
the tissue repository will allow tissue specific epigenetic
and gene expression studies for T2D. Moreover, the
superimposition of GWAS data with these exhaustive
epigenetic and proteomics profiling will help us understand
the correlation between the genome, proteome and epige-
nome, thus revealing example of gene environment inter-
action. This will be crucial in developing a complete
picture of the disease leading to better treatment and
healthcare policy.
Summary
The consortium deemed the resource fabrication pertinent
to divulge the risk factors accountable for the high vul-
nerability of Indians to T2D by identifying pre-diagnostic
markers at genetic, epigenetic, metabolite and proteomic
levels for managing T2D and other related life style dis-
orders. We also hope that INDICO will eventually be of
value to not just the diabetes research community but
would be able to contribute towards an improved under-
standing, diagnosis and prevention of numerous complex
human disorders.
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Fig. 2 Change in average cholesterol levels and Hb1Ac in sample
population during the time scale of INDICO sample collection and
Gross Domestic Product (GDP) growth of Indian economy
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